Latest Centocor Stories
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
QUEENSLAND, Australia, Oct.
Acquisition Strengthens Existing Pipeline in Viral Diseases NEW BRUNSWICK, N.J., Sept.
NEW BRUNSWICK, N.J., Sept. 3, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Morgan Stanley Health Care Conference on Wednesday, Sept.
BioScience Laboratories, Inc.
Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON,
NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the
-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics
The Firm is representing hundreds of women who have filed vaginal mesh lawsuits against Johnson & Johnson’s Ethicon unit in state and federal courts. New
- Emitting flashes of light; glittering.